{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T09:56:57Z","timestamp":1756893417030,"version":"3.37.3"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007560","name":"Chiesi Farmaceutici","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007560","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.phrs.2021.105915","type":"journal-article","created":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T11:46:44Z","timestamp":1632743204000},"page":"105915","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Switching to nebulised short acting bronchodilators does not increase the risk of arrhythmia in patients hospitalized with a COPD exacerbation"],"prefix":"10.1016","volume":"173","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3462-8253","authenticated-orcid":false,"given":"Pierachille","family":"Santus","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5353-4717","authenticated-orcid":false,"given":"Elisa","family":"Franceschi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Pini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Frassanito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Amati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiammetta","family":"Danzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Gatti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9013-3418","authenticated-orcid":false,"given":"Dejan","family":"Radovanovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2021.105915_bib1","unstructured":"Global Initiative for Chronic Obstructive Lung Disease, Global Strategy for Prevention, Diagnosis and management of COPD, 2021. Available at \u3008https:\/\/goldcopd.org\/wp-content\/uploads\/2020\/11\/GOLD-REPORT-2021-v1.1\u201325Nov20_WMV.pdf\u3009."},{"key":"10.1016\/j.phrs.2021.105915_bib2","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1136\/thx.2009.128082","article-title":"Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care","volume":"65","author":"Feary","year":"2010","journal-title":"Thorax"},{"key":"10.1016\/j.phrs.2021.105915_bib3","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1080\/15412555.2019.1659760","article-title":"Clinical and functional characteristics of COPD patients across GOLD classifications: results of a multicenter observational study","volume":"16","author":"Radovanovic","year":"2019","journal-title":"COPD"},{"key":"10.1016\/j.phrs.2021.105915_bib4","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S2213-2600(15)00518-4","article-title":"Cardiac effects of current treatments of chronic obstructive pulmonary disease","volume":"4","author":"Lahousse","year":"2016","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.phrs.2021.105915_bib5","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1093\/eurheartj\/ehaa822","article-title":"Chronic obstructive pulmonary disease and atrial fibrillation: an interdisciplinary perspective","volume":"42","author":"Simons","year":"2021","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.phrs.2021.105915_bib6","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1378\/chest.11-1597","article-title":"Bronchodilator use and the risk of arrhythmia in COPD: part 2: reassessment in the larger Quebec cohort","volume":"142","author":"Wilchesky","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.phrs.2021.105915_bib7","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1378\/chest.08-2367","article-title":"Cardiovascular events associated with ipratropium bromide in COPD","volume":"137","author":"Ogale","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.phrs.2021.105915_bib8","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.amjcard.2014.04.030","article-title":"Relation of chronic obstructive pulmonary disease to atrial and ventricular arrhythmias","volume":"114","author":"Konecny","year":"2014","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.phrs.2021.105915_bib9","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ahj.2016.08.011","article-title":"Impact of chronic obstructive pulmonary disease on prognosis in atrial fibrillation: a report from the EURObservational Research Programme Pilot Survey on Atrial Fibrillation (EORP-AF) General Registry","volume":"181","author":"Proietti","year":"2016","journal-title":"Am. Heart J."},{"key":"10.1016\/j.phrs.2021.105915_bib10","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ijcard.2018.09.056","article-title":"Chronic obstructive pulmonary disease and the development of atrial fibrillation","volume":"276","author":"Grymonprez","year":"2019","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.phrs.2021.105915_bib11","first-page":"2908","article-title":"Atrial fibrillation in the acute, hypercapnic exacerbations of COPD","volume":"18","author":"Terzano","year":"2014","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.phrs.2021.105915_bib12","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s40265-017-0731-3","article-title":"Management of chronic obstructive pulmonary disease in patients with cardiovascular diseases","volume":"77","author":"Cazzola","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.phrs.2021.105915_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105306","article-title":"Association between anticholinergic burden and anticholinergic adverse outcomes in the elderly: pharmacological basis of their predictive value for adverse outcomes","volume":"163","author":"Lavrador","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2021.105915_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.pupt.2019.101841","article-title":"Efficacy and cardiovascular safety profile of dual bronchodilation therapy in chronic obstructive pulmonary disease: a bidimensional comparative analysis across fixed-dose combinations","volume":"59","author":"Rogliani","year":"2019","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2021.105915_bib15","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1164\/rccm.201609-1794CI","article-title":"How do dual long-acting bronchodilators prevent exacerbations of chronic obstructive pulmonary disease?","volume":"196","author":"Beeh","year":"2017","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.phrs.2021.105915_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104785","article-title":"Choosing among \u03b2-blockers in heart failure patients according to \u03b2-receptors\u2019 location and functions in the cardiopulmonary system","volume":"156","author":"Sinagra","year":"2020","journal-title":"Pharmacol. Res."},{"issue":"46","key":"10.1016\/j.phrs.2021.105915_bib17","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1093\/eurheartj\/ehaa793","article-title":"Association of beta-blocker use with survival and pulmonary function in patients with chronic obstructive pulmonary and cardiovascular disease: a systematic review and meta-analysis","volume":"41","author":"Yang","year":"2020","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.phrs.2021.105915_bib18","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.pupt.2006.02.002","article-title":"Doppler echocardiographic assessment of the effects of inhaled long-acting beta2-agonists on pulmonary artery pressure in COPD patients","volume":"20","author":"Cazzola","year":"2007","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2021.105915_bib19","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.rmed.2005.10.008","article-title":"Comparison of the acute effect of tiotropium versus a combination therapy with single inhaler budesonide\/formoterol on the degree of resting pulmonary hyperinflation","volume":"100","author":"Santus","year":"2006","journal-title":"Respir. Med."},{"key":"10.1016\/j.phrs.2021.105915_bib20","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.2147\/COPD.S91684","article-title":"Effect of indacaterol on lung deflation improves cardiac performance in hyperinflated COPD patients: an interventional, randomized, double-blind clinical trial","volume":"10","author":"Santus","year":"2015","journal-title":"Int. J. Chron. Obstr. Pulm. Dis."},{"key":"10.1016\/j.phrs.2021.105915_bib21","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1152\/japplphysiol.00493.2017","article-title":"Acute effects of long-acting bronchodilators on small airways detected in COPD patients by single-breath N2 test and lung P-V curve","volume":"123","author":"Pecchiari","year":"1985","journal-title":"J. Appl. Physiol."},{"key":"10.1016\/j.phrs.2021.105915_bib22","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD011826.pub2","article-title":"Bronchodilators delivered by nebuliser versus pMDI with spacer or DPI for exacerbations of COPD","author":"van Geffen","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.phrs.2021.105915_bib23","doi-asserted-by":"crossref","first-page":"A158","DOI":"10.1136\/thoraxjnl-2012-202678.277","article-title":"Impact of tachycardia and new onset atrial fibrillation in acute exacerbations of COPD","volume":"67","author":"Short","year":"2012","journal-title":"Thorax"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661821004990?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661821004990?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T01:49:26Z","timestamp":1734400166000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661821004990"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":23,"alternative-id":["S1043661821004990"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2021.105915","relation":{},"ISSN":["1043-6618"],"issn-type":[{"type":"print","value":"1043-6618"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Switching to nebulised short acting bronchodilators does not increase the risk of arrhythmia in patients hospitalized with a COPD exacerbation","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2021.105915","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105915"}}